|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brody H: Colorectal cancer. Nature.
521(S1)2015.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Pourhoseingholi MA: Increased burden of
colorectal cancer in Asia. World J Gastrointest Oncol. 4:68–70.
2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
García-Osogobio S, Téllez-Ávila FI, Méndez
N and Uribe-Esquivel M: Results of the first program of colorectal
cancer screening in Mexico. Endoscopia. 27:59–63. 2015.
|
|
5
|
Arnold D, Prager GW, Quintela A, Stein A,
Vera SM, Mounedji N and Taieb J: Beyond second-line therapy in
patients with metastatic colorectal cancer: A systematic review.
Ann Oncol. 29:835–856. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stintzing S: Management of colorectal
cancer. F1000Prime Rep. 6(108)2014.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Vodenkova S, Buchler T, Cervena K,
Veskrnova V, Vodicka P and Vymetalkova V: 5-fluorouracil and other
fluoropyrimidines in colorectal cancer: Past, present and future.
Pharmacol Ther. 206(107447)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liu C, Zhao Y, Wang J, Yang Y, Zhang Y, Qu
X, Peng S, Yao Z, Zhao S, He B, et al: FoxO3 reverses
5-fluorouracil resistance in human colorectal cancer cells by
inhibiting the Nrf2/TR1 signaling pathway. Cancer Lett. 470:29–42.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang XJ, Reyes JL, Chua NH and Gaasterland
T: Prediction and identification of arabidopsis thaliana microRNAs
and their mRNA targets. Genome Biol. 5(R65)2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Trang P, Weidhaas JB and Slack FJ:
MicroRNAs as potential cancer therapeutics. Oncogene. 27 (Suppl
2):S52–S57. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Barisciano G, Colangelo T, Rosato V,
Muccillo L, Taddei ML, Ippolito L, Chiarugi P, Galgani M,
Bruzzaniti S, Matarese G, et al: miR-27a is a master regulator of
metabolic reprogramming and chemoresistance in colorectal cancer.
Br J Cancer. 122:1354–1366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu T, Zhang X, Du L, Wang Y, Liu X, Tian
H, Wang L, Li P, Zhao Y, Duan W, et al: Exosome-transmitted
miR-128-3p increase chemosensitivity of oxaliplatin-resistant
colorectal cancer. Mol Cancer. 18(43)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Choi Y, Choi HS, Jeon WK, Kim BI, Park DI,
Cho YK, Kim HJ, Park JH and Sohn CI: Optimal number of endoscopic
biopsies in diagnosis of advanced gastric and colorectal cancer. J
Korean Med Sci. 27:36–39. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xie P, Mo JL, Liu JH, Li X, Tan LM, Zhang
W, Zhou HH and Liu ZQ: Pharmacogenomics of 5-fluorouracil in
colorectal cancer: Review and update. Cell Oncol (Dordr).
43:989–1001. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Blondy S, David V, Verdier M, Mathonnet M,
Perraud A and Christou N: 5-Fluorouracil resistance mechanisms in
colorectal cancer: From classical pathways to promising processes.
Cancer Sci. 111:3142–3154. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhao P, Ma YG, Zhao Y, Liu D, Dai ZJ, Yan
CY and Guan HT: MicroRNA-552 deficiency mediates 5-fluorouracil
resistance by targeting SMAD2 signaling in
DNA-mismatch-repair-deficient colorectal cancer. Cancer Chemother
Pharmacol. 84:427–439. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liu G, Zhou J and Dong M: Down-regulation
of miR-543 expression increases the sensitivity of colorectal
cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway.
Biosci Rep. 39(BSR20190249)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dermani FK and Najafi R: miR-200c as a
predictive biomarker for 5-Fluorouracil chemosensitivity in
colorectal cancer. J Gastrointest Cancer. 49:102–103.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
van Lohuizen M, Verbeek S, Krimpenfort P,
Domen J, Saris C, Radaszkiewicz T and Berns A: Predisposition to
lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc
and N-myc in murine leukemia virus-induced tumors. Cell.
56:673–682. 1989.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Herzog S, Fink MA, Weitmann K, Friedel C,
Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, et
al: Pim1 kinase is upregulated in glioblastoma multiforme and
mediates tumor cell survival. Neuro Oncol. 17:223–242.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jiang R, Wang X, Jin Z and Li K:
Association of nuclear PIM1 expression with lymph node metastasis
and poor prognosis in patients with lung adenocarcinoma and
squamous cell carcinoma. J Cancer. 7:324–334. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhang M, Liu T, Sun H, Weng W, Zhang Q,
Liu C, Han Y and Sheng W: Pim1 supports human colorectal cancer
growth during glucose deprivation by enhancing the warburg effect.
Cancer Sci. 109:1468–1479. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gu JJ, Wang Z, Reeves R and Magnuson NS:
PIM1 phosphorylates and negatively regulates ASK1-mediated
apoptosis. Oncogene. 28:4261–4271. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li Q, Chen L, Luo C, ChenYan Ge J, Zhu Z,
Wang K, Yu X, Lei J, Liu T, et al: TAB3 upregulates PIM1 expression
by directly activating the TAK1-STAT3 complex to promote colorectal
cancer growth. Exp Cell Res. 391(111975)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Braso-Maristany F, Filosto S, Catchpole S,
Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L,
Gazinska P, Liccardi G, et al: PIM1 kinase regulates cell death,
tumor growth and chemotherapy response in triple-negative breast
cancer. Nat Med. 22:1303–1313. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Blanco FF, Jimbo M, Wulfkuhle J, Gallagher
I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I,
Sawicki JA, et al: The mRNA-binding protein HuR promotes
hypoxia-induced chemoresistance through posttranscriptional
regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
Oncogene. 35:2529–2541. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Weirauch U, Beckmann N, Thomas M,
Grünweller A, Huber K, Bracher F, Hartmann RK and Aigner A:
Functional role and therapeutic potential of the pim-1 kinase in
colon carcinoma. Neoplasia. 15:783–794. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Núñez-Olvera SI, Chávez-Munguía B, Del
Rocío Terrones-Gurrola MC, Marchat LA, Puente-Rivera J, Ruíz-García
E, Campos-Parra AD, Vázquez-Calzada C, Lizárraga-Verdugo ER,
Ramos-Payán R, et al: A novel protective role for microRNA-3135b in
golgi apparatus fragmentation induced by chemotherapy via
GOLPH3/AKT1/mTOR axis in colorectal cancer cells. Sci Rep.
10(10555)2020.PubMed/NCBI View Article : Google Scholar
|
